IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH-Reference-Cited by-同舟云学术

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Published:2022-07-17 Issue:1 Volume:77 Page:20-32
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:

Author:

Xu Jun,Wang Ya,Khoshdeli Mina,Peach Matt,Chuang Jen‐Chieh,Lin Julie,Tsai Wen‐Wei,Mahadevan Sangeetha,Minto Wesley,Diehl Lauri,Gupta Ruchi,Trauner Michael,Patel Keyur,Noureddin Mazen,Kowdley Kris V.,Gulamhusein Aliya,Bowlus Christopher L.,Huss Ryan S.,Myers Robert P.,Chung Chuhan,Billin Andrew N.

Funder

Gilead Sciences

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.32599

Reference42 articles.

1. Pruritus in cholestasis: facts and fiction;Hepatology,2014

2. A placebo‐controlled trial of obeticholic acid in primary biliary cholangitis;N Engl J Med,2016

3. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid;Gastroenterology,2015

4. A randomized, placebo‐controlled, phase II study of obeticholic acid for primary sclerosing cholangitis;J Hepatol,2020

5. The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): a phase 2, randomized, placebo‐controlled trial;Hepatology,2019

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis;Metabolism Open;2024-03

2. Bile Acids in Autoimmune Liver Disease: Unveiling the Nexus of Inflammation, Inflammatory Cells, and Treatment Strategies;Cells;2023-11-29

3. FXR agonists in NASH treatment;Journal of Hepatology;2023-11

4. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid;Medicinal Research Reviews;2023-10-30

5. Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved;Hepatobiliary Surgery and Nutrition;2023-10